BRIEF—New long-term data for Cosentyx in ankylosing spondylitis

Novartis has announced new long-term Cosentyx (secukinumab) data for patients with ankylosing spondylitis.

Chief medical officer Vas Narasimhan said: "For the first time for any biologic, Cosentyx shows that almost 80% of patients had no radiographic progression for as long as four years.”

The data, from the MEASURE 1 study, also confirm sustained improvement in signs and symptoms in almost 80% of patients.

Cosentyx is the only IL-17A inhibitor approved for this condition, in over 70 countries.